204 related articles for article (PubMed ID: 32349843)
1. State strategies to address medicaid prescription spending: negotiated pricing vs price transparency.
Noh S; Janousek CL; Park JH
Health Econ Policy Law; 2021 Apr; 16(2):201-215. PubMed ID: 32349843
[TBL] [Abstract][Full Text] [Related]
2. Evolving Medicaid Coverage Policy and Rebates.
Ohn JA; Kaltenboeck A
AMA J Ethics; 2019 Aug; 21(8):E645-653. PubMed ID: 31397659
[TBL] [Abstract][Full Text] [Related]
3. Estimates of Medicaid and Non-Medicaid Net Prices of Top-Selling Brand-name Drugs Incorporating Best Price Rebates, 2015 to 2019.
Clemans-Cope L; Epstein M; Banthin J; Kesselheim AS; Hwang TJ
JAMA Health Forum; 2023 Jan; 4(1):e225012. PubMed ID: 36637815
[TBL] [Abstract][Full Text] [Related]
4. Pursuing Value-Based Prices for Drugs: A Comprehensive Comparison of State Prescription Drug-Pricing Boards.
Bendicksen L; Rome BN; Avorn J; Kesselheim AS
Milbank Q; 2021 Dec; 99(4):1162-1197. PubMed ID: 34375015
[TBL] [Abstract][Full Text] [Related]
5. The Medicaid Rebate: Changes in Oncology Drug Prices After the Affordable Care Act.
Bonakdar Tehrani A; Carroll NV
Appl Health Econ Health Policy; 2017 Aug; 15(4):513-520. PubMed ID: 28224469
[TBL] [Abstract][Full Text] [Related]
6. A Review of US Drug Costs Relevant to Medicare, Medicaid, and Commercial Insurers Post-Affordable Care Act Enactment, 2010-2016.
McRae J; Vogenberg FR; Beaty SW; Mearns E; Varga S; Pizzi L
Pharmacoeconomics; 2017 Feb; 35(2):215-223. PubMed ID: 27798809
[TBL] [Abstract][Full Text] [Related]
7. The Effect of Florida Medicaid's State-Mandated Formulary Provision on Prescription Drug Use and Health Plan Costs in a Medicaid Managed Care Plan.
Munshi KD; Mager D; Ward KM; Mischel B; Henderson RR
J Manag Care Spec Pharm; 2018 Feb; 24(2):124-131. PubMed ID: 29384030
[TBL] [Abstract][Full Text] [Related]
8. Medicaid prescription drug coverage: state efforts to control costs.
Gencarelli DM
NHPF Issue Brief; 2003 May; (790):1-17. PubMed ID: 12751504
[TBL] [Abstract][Full Text] [Related]
9. States on the Front Line: Addressing America's Drug Pricing Problem.
Riley T; Lanford S
J Leg Med; 2019; 39(2):81-93. PubMed ID: 31503529
[No Abstract] [Full Text] [Related]
10. Why France Spends Less Than the United States on Drugs: A Comparative Study of Drug Pricing and Pricing Regulation.
Raimond VC; Feldman WB; Rome BN; Kesselheim AS
Milbank Q; 2021 Mar; 99(1):240-272. PubMed ID: 33751664
[TBL] [Abstract][Full Text] [Related]
11. How do state Medicaid programs determine what substance use disorder treatment medications need prior authorization? An overview for clinicians.
Bachhuber MA
Addict Sci Clin Pract; 2020 Jun; 15(1):20. PubMed ID: 32600402
[TBL] [Abstract][Full Text] [Related]
12. Enrollment is driving Medicaid costs--but two targets can yield savings.
Holahan J; Yemane A
Health Aff (Millwood); 2009; 28(5):1453-65. PubMed ID: 19738264
[TBL] [Abstract][Full Text] [Related]
13. Differences Between Managed Care and Fee-for-Service Medicaid in the Use of Generics for High-Rebate Drugs: The Cases of Insulin Glargine and Glatiramer.
Hernandez I; Gellad WF
J Manag Care Spec Pharm; 2020 Feb; 26(2):154-159. PubMed ID: 32011961
[TBL] [Abstract][Full Text] [Related]
14. One pill, many prices: variation in prescription drug prices in selected government programs.
Gencarelli DM
Issue Brief George Wash Univ Natl Health Policy Forum; 2005 Aug; (807):1-20. PubMed ID: 16167399
[TBL] [Abstract][Full Text] [Related]
15. Pharmaceuticals: pharmaceutical cost controls--2005. End of Year Issue Brief.
Seay M; Varma P
Issue Brief Health Policy Track Serv; 2005 Dec; ():1-20. PubMed ID: 16708455
[TBL] [Abstract][Full Text] [Related]
16. AMCP Guide to Pharmaceutical Payment Methods, 2009 Update (Version 2.0).
Academy of Managed Care Pharmacy
J Manag Care Pharm; 2009 Aug; 15(6 Suppl A):S3-57, quiz S58-61. PubMed ID: 19678720
[TBL] [Abstract][Full Text] [Related]
17. Differences in the cost of antidepressants across state Medicaid programs.
Kelton CM; Rebelein RP; Heaton PC; Ferrand Y; Guo JJ
J Ment Health Policy Econ; 2008 Mar; 11(1):33-47. PubMed ID: 18424875
[TBL] [Abstract][Full Text] [Related]
18. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.
Kesselheim AS; Avorn J; Sarpatwari A
JAMA; 2016 Aug 23-30; 316(8):858-71. PubMed ID: 27552619
[TBL] [Abstract][Full Text] [Related]
19. States as Activists.
Buck ID
J Leg Med; 2019; 39(2):121-136. PubMed ID: 31503528
[TBL] [Abstract][Full Text] [Related]
20. Abandoning List Prices In Medicaid Drug Reimbursement Did Not Affect Spending.
Ippolito B; Levy JF; Anderson GF
Health Aff (Millwood); 2020 Jul; 39(7):1202-1209. PubMed ID: 32634350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
